Lipoglycopeptide antibiotic
Oritavancin
Brand names: Orbactiv, Tenkasi
Adult dose
Dose: 1.2g IV single dose over 3h (Orbactiv)
Route: IV
Frequency: single
Clinical pearls
- Acute bacterial skin and soft-tissue infection (single-dose alternative to IV vancomycin daily)
- Specialist micro / OPAT
Contraindications
- Hypersensitivity to glycopeptides
- Concurrent IV unfractionated heparin (next 48h — interferes with aPTT)
Side effects
- Headache
- Nausea
- Infusion reactions
- Hepatotoxicity
- Osteomyelitis (rare)
Interactions
- Warfarin (raised INR)
- Heparin (interferes with aPTT for 48h)
Monitoring
- Clinical response
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/oritavancin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Gustilo-Anderson Classification (Open Fractures) · Fracture Classification
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023